Mouth and oropharyngeal Cancer
FEATURES
avatar
1284 clinical trials
avatar
127 cell line models
avatar
13 approved drugs
IMAGE
Mouth and oropharyngeal Cancer
Molecular Synopsis
OVERVIEW
Drugs and clinical candidates

13 drugs have received FDA approval for Mouth and oropharyngeal Cancer:

  • Amifostine
  • Docetaxel
  • Hydroxyurea
  • Ipilimumab
  • Leucovorin Calcium
More

194 drugs have a clinical trial registered for Mouth and oropharyngeal Cancer.

20025 compounds have been tested in Mouth and oropharyngeal Cancer (15078 <= 500nM potency).

Sources: cancer.gov, clinicaltrials.gov, ChEMBL.

Clinical trials
There are 1284 clinical trials for Mouth and oropharyngeal Cancer, 670 of which have one or more drug interventions, 614 with no drug intervention.
Cell line models

There are 127 Cell Line Models for Mouth and oropharyngeal Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Mouth and oropharyngeal Cancer:
  • Esophageal Squamous Cell Carcinoma
  • Lip Neoplasms
  • Esophageal Neoplasms
  • Hypopharyngeal Neoplasms
  • Mouth Neoplasms
More
The following terms have been mapped from cancer.gov to Mouth and oropharyngeal Cancer:
  • Squamous cell carcinoma of the head and neck (excluding the lip) that is locally advanced. It is used with chemoradiation
  • Colorectal cancer in adults and children 12 years and older. It is used alone or with ipilimumab to treat metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride
  • Colorectal cancer in adults and children 12 years and older. It is used with nivolumab to treat metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride
  • Colorectal cancer that has metastasized (spread to other parts of the body). It is used in adults who have already been treated with a fluoropyrimidine, oxaliplatin, irinotecan hydrochloride, and an anti-VEGF biologic therapy. Patients whose cancer does not have a mutation in the RAS gene should have also received an anti-EGFR therapy
  • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse after treatment with a fluoropyrimidine or platinum chemotherapy. It is used alone or with paclitaxel
More